On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia, had successfully passed the first scheduled independent Safety Monitoring Committee (SMC) review.

The Company also announced it had received approval from the Italian Medicines Agency (AIFA) for its Clinical Trial Authorization (CTA) application for the global Phase 2/3 study evaluating opaganib in patients hospitalized with severe COVID-19 pneumonia, for which patient enrollment has already commenced.